Evidence map›Paper›PMID 25639353›Full record

ArticleThe FEBS journal2015

Active ERK2 is sufficient to mediate growth arrest and differentiation signaling.

Pui-Kei Wu, Seung-Keun Hong, Seung-Hee Yoon, Jong-In Park

Open access · bronzeAbstract read
In one paragraph

Article in The FEBS journal, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
1.1field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 23 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Tumor Cell Resistance to the Inhibition of BRAF and MEK1/2.International journal of molecular sciences · 2023
    Review
  5. Article
  6. Article
  7. Protein Kinase-Mediated Decision Between the Life and Death.Advances in experimental medicine and biology · 2021
    Article
  8. Growth Inhibitory Signaling of the Raf/MEK/ERK Pathway.International journal of molecular sciences · 2020
    Review
  9. Targeting ERK-Hippo Interplay in Cancer Therapy.International journal of molecular sciences · 2020
    Review
  10. Mortalin (HSPA9) facilitatesScience signaling · 2020
    Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Pui-Kei WuDepartment of Biochemistry, Medical College of Wisconsin, Milwaukee, WI, USA.
Seung-Keun Hong
Seung-Hee Yoon
Jong-In Park
Medical College of Wisconsin · US

Funding

Mechanisms of MEK/ERK growth arrest signalingR01CA138441 · NCI · MEDICAL COLLEGE OF WISCONSIN · PI PARK, JONG-IN · 2010 to 2020
$2.9M
NCI NIH HHS R01 CA138441NCI NIH HHS R01CA138441
6 · The paper itself

Abstract

Although extracellular signal-regulated kinases (ERK1/2) have been shown to be required in Raf/MEK/ERK pathway signaling, its sufficiency for mediating the pathway signaling has not been firmly established. In an effort to address this, we evaluated previously described ERK2 mutants that exhibit enhanced autophosphorylation of TEY sites in the activation loop in terms of their ability to induce growth arrest and differentiation in LNCaP and PC12 cells. We demonstrate that expression of ERK2-L73P/S151D, containing Lys73Pro and Ser151Asp substitutions that synergistically promote ERK autophosphorylation, is sufficient to induce growth arrest and differentiation, whereas expression of ERK2-I84A and ERK2-R65S/D319N is not as effective. When compared to the constitutively active MEK1-ΔN3/S218E/S222D, expression of ERK2-L73P/S151D only mildly increased ERK kinase activity in cells, as assessed using the ERK substrates p90(RSK) and ETS domain-containing protein (ELK1). However, ERK2-L73P/S151D expression effectively induced down-regulation of androgen receptors, Retinoblastoma (Rb) protein and E2F1 transcription factor, and up-regulation of p16(INK4A) and p21(CIP1), accompanied by cell-cycle arrest and morphological differentiation in LNCaP cells and neurite-like processes in PC12 cells. These effects and the TEY site phosphorylation of ERK2-L73P/S151D were abrogated upon introduction of the active site-disabling Lys52Arg mutation, suggesting that its autoactivation drives this signaling. Moreover, introduction of mutations Asp316/319Ala or Asp319Asn, which impair the common docking site/D-domain-based physical interaction of ERK, did not significantly affect ERK2-L73P/S151D signaling, suggesting that ERK2 mediates growth arrest and differentiation independently of the conventional ERK-target interaction mechanism. Thus, our study presents convincing evidence of ERK sufficiency for Raf/MEK/ERK signaling.

Indexed as

Cell DifferentiationCell ProliferationMAP Kinase Signaling SystemAnimalsBinding SitesCell CycleCell Line, TumorCellular SenescenceHEK293 CellsHumansMaleMutationPC12 CellsPhosphorylationPlasmidsProtein Structure, Tertiaryraf KinasesReceptors, AndrogendifferentiationERK/MAPKgrowth arrestMEKRaf

Identifiers

PMID25639353
PMCPMC4368470
OpenAlexW2056507922

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.